Kymera Therapeutics ( (KYMR) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Kymera Therapeutics has experienced a notable drop in stock prices due to its recent financial results, which showed a decrease in revenue and an increased net loss. Despite these concerning figures, analysts have mixed ratings for the company. While Truist Financial and Stifel Nicolaus issued Buy ratings, Bank of America Securities remains cautious with a Hold rating. The average price target stands at $59.40, indicating optimism in Kymera’s innovative biotech strategies and future growth potential.
More about Kymera Therapeutics
YTD Price Performance: 6.53%
Average Trading Volume: 461,645
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.6B
For further insights into KYMR stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.